NEUROONE MEDICAL TECHNOLOGIES Corp - Common Stock, par value, $0.001 per share (NMTC)
CUSIP: 64130M209
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value, $0.001 per share
- Shares outstanding
- 50,013,453
- Total 13F shares
- 13,532,500
- Share change
- +11,603,173
- Total reported value
- $9,178,137
- Put/Call ratio
- 0%
- Price per share
- $0.68
- Number of holders
- 30
- Value change
- +$7,852,763
- Number of buys
- 19
- Number of sells
- 2
Quarterly Holders Quick Answers
What is CUSIP 64130M209?
CUSIP 64130M209 identifies NMTC - NEUROONE MEDICAL TECHNOLOGIES Corp - Common Stock, par value, $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 64130M209:
Top shareholders of NMTC - NEUROONE MEDICAL TECHNOLOGIES Corp - Common Stock, par value, $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Bleichroeder LP |
13D/G
|
— |
8%
|
4,000,000
|
$2,800,000 | $0 | 30 Jun 2025 | |
| MERCHANT ADVENTURE FUND, L.P. |
13D/G
|
— |
14%
|
4,200,000
|
$2,478,000 | $0 | 31 Dec 2024 | |
| AWM Investment Company, Inc. |
13D/G
13F
|
Company |
4.8%
|
2,354,167
|
$1,388,959 | $0 | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.2%
|
1,110,690
|
$944,087 | — | 31 Mar 2025 | |
| MANCHESTER MANAGEMENT CO LLC |
13D/G
|
JAMES E. BESSER |
4.9%
|
1,583,332
|
$934,166 | $0 | 31 Dec 2024 | |
| Laurence W. Lytton |
13D/G
|
LYTTON LAURENCE W |
2.6%
|
1,295,288
|
$764,220 | $0 | 31 Mar 2025 | |
| Nantahala Capital Management, LLC |
13D/G
|
— |
2.6%
|
798,762
|
$471,270 | $0 | 30 Sep 2024 | |
| Ronald W. McClurg |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
694,117
mixed-class rows
|
$377,588 | — | 17 Apr 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.69%
|
345,976
|
$294,219 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.2%
|
98,573
|
$83,807 | — | 31 Mar 2025 | |
| Cambridge Investment Research Advisors, Inc. |
13F
|
Company |
0.16%
|
81,000
|
$69,000 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.12%
|
59,499
|
$50,586 | — | 31 Mar 2025 | |
| BLAIR WILLIAM & CO/IL |
13F
|
Company |
0.11%
|
55,556
|
$47,234 | — | 31 Mar 2025 | |
| MAI Capital Management |
13F
|
Company |
0.1%
|
50,000
|
$42,510 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.1%
|
48,973
|
$41,637 | — | 31 Mar 2025 | |
| J.W. COLE ADVISORS, INC. |
13F
|
Company |
0.07%
|
37,120
|
$31,559 | — | 31 Mar 2025 | |
| Princeton Global Asset Management LLC |
13F
|
Company |
0.03%
|
16,833
|
$14,311 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.02%
|
11,946
|
$10,156 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.02%
|
10,107
|
$8,593 | — | 31 Mar 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
1,333
|
$1,133 | — | 31 Mar 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
1,259
|
$1,069 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
290
|
$246 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
108
|
$92 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
61
|
$52 | — | 31 Mar 2025 | |
| Vermillion Wealth Management, Inc. |
13F
|
Company |
0%
|
3
|
$3 | — | 31 Mar 2025 | |
| Christopher Volker |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
575,000
|
— | — | 17 Apr 2025 | |
| Emily J. Johns |
3/4/5
|
General Counsel |
—
class O/S missing
|
500,000
|
— | — | 01 Jun 2025 |
Institutional Holders of NEUROONE MEDICAL TECHNOLOGIES Corp - Common Stock, par value, $0.001 per share (NMTC) as of Q2 2025
As of 30 Jun 2025,
NEUROONE MEDICAL TECHNOLOGIES Corp - Common Stock, par value, $0.001 per share (NMTC) was held by
30 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
13,532,500 shares.
The largest 10 holders included
Bleichroeder LP, Sio Capital Management, LLC, BARD ASSOCIATES INC, PERKINS CAPITAL MANAGEMENT INC, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, Cambridge Investment Research Advisors, Inc., XTX Topco Ltd, and CITADEL ADVISORS LLC.
This page lists
30
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
18
Q2 2025 holders
30
Holder diff
12
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.